OncoCyte (OncoCyte) Debt-to-Asset

: 0.04 (As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

OncoCyte's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.67 Mil. OncoCyte's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $2.20 Mil. OncoCyte's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Dec. 2023 was $74.89 Mil. OncoCyte's debt to asset for the quarter that ended in Dec. 2023 was 0.04.

OncoCyte Debt-to-Asset Historical Data

The historical data trend for OncoCyte's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OncoCyte Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Asset

0.15

0.16

0.04

OncoCyte Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Asset																0.04	0.04	0.04	0.04	0.04

Competitive Comparison

For the Diagnostics & Research subindustry, OncoCyte's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

OncoCyte Debt-to-Asset Distribution

For the Medical Diagnostics & Research industry and Healthcare sector, OncoCyte's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where OncoCyte's Debt-to-Asset falls into.

OncoCyte Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

OncoCyte's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0.665	+	2.204)	/	74.892
	=	0.04

OncoCyte's Debt-to-Asset for the quarter that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0.665	+	2.204)	/	74.892
	=	0.04

OncoCyte (NAS:OCX) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

OncoCyte Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of OncoCyte's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

OncoCyte (OncoCyte) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » OncoCyte Corp (NAS:OCX) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

15 Cushing, Irvine, CA, USA, 92618

Website

https://www.oncocyte.com

OncoCyte Corp focuses on the discovery, development, and commercialization of novel, non-invasive, liquid biopsy diagnostics for the early detection of cancer. The company develops diagnostic tests based on liquid biopsies using blood or urine samples for detecting lung, bladder, and breast cancers. In addition, it also develops screening diagnostics as potential replacements for screening imaging procedures that do not meet the needs of patients, health care providers or payers. Geographically operation of the group is carried through the United States.

Executives

John Peter Gutfreund	other: Former Director	767 5TH AVENUE, 44TH FLOOR, NEW YORK NY 10153
Alfred D Kingsley	director	150 E 57TH STREET, NEW YORK NY 10022
Pura Vida Investments, Llc	10 percent owner	512 W 22ND STREET, 7TH FLOOR, NEW YORK NY 10011
Broadwood Partners Lp	10 percent owner	BROADWOOD CAPITAL INC., 142 WEST 57TH STREET, 11TH FLOOR, NEW YORK NY 10019
Andrew Arno	director	C/O MERRIMAN CURHAN FORD GROUP, INC., 600 CALIFORNIA STREET, 9TH FLOOR, SAN FRANCISCO CA 94108
Josh Riggs	officer: Interim CEO	15 CUSHING, IRVINE CA 92618
Lou Silverman	director
James Yang Liu	officer: Controller, PAO	C/O ONCOCYTE CORPORATION, 15 CUSHING, IRVINE CA 92618
Andrew J. Last	director	3420 CENTRAL EXPRESSWAY, SANTA CLARA CA 95051
Jennifer L. Carter	director	C/O DFP SPONSOR LLC, 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Ronald Asbury Andrews	director	5791 VAN ALLEN WAY, CARLSBAD CA 92008
Melinda Griffith	director	1010 ATLANTIC AVENUE, SUITE 102, ALAMEDA CA 94501
Anish M. John	officer: SVP, Finance, and Interim CFO	C/O ONCOCYTE CORPORATION,, 15 CUSHING, IRVINE CA 92618
Li Yu	officer: VP Cntrllr/Prncpl Acctng Offcr	120 NEWPORT CENTER DRIVE., NEWPORT BEACH CA 92660
Efrem Kamen	10 percent owner	C/O PURA VIDA INVESTMENTS, LLC, 512 W 22ND STREET, 7TH FLOOR, NEW YORK NY 10011